the FDA granted 1749 OD designations and 315 OD approvals for marketing. NCEs accounted for 17.7% of OD designations and 53.7% of OD approvals. The FDA approved 635 NCEs in the study period, out of which 17.5% had OD status at the first NDA approval. Sponsors of ODs were more likely (p < 0.001) to be US companies as compared to non-US companies (64.0% vs. 54.4%) and to have one NCE approval as compared to multiple NCE during the study period (43.2% vs. 17.6%). ODs were less likely (p < 0.001) to have at least one patent listed in the OB in comparison with non-ODs (62.2% vs. 82.8%). ODs had less patents listed in the OB than non-ODs (mean 1.7 vs. 2.3) (p < 0.005). Exclusivity period was longer than the patent period for 41.4% of the ODs and 21.4% of the non-ODs that had patents listed in the OB (p < 0.001). ODs had less generic competition than non-ODs (18.0% vs. 29.6%) (p < 0.05). CON-CLUSION: US companies and companies with only one NCE approval were more likely to use the Orphan drug regulatory system. Orphan drugs have less number of patents, more exclusivity protection and less generic competition than non-orphan drugs.
1 Kaiser Permanente Colorado, Aurora, CO, USA, 2 Kaiser Permanente Colorado, Denver, CO, USA OBJECTIVE: To compare health care utilization changes between Medicare beneficiaries with two prescription drug benefit structures who did and did not reach their respective Part D drug benefit spend threshold in 2006. METHODS: A retrospective analysis of a cohort of 28,392 Medicare Advantage beneficiaries continuously enrolled into two distinct drug benefit structures for the year prior to and after implementation of the Medicare Part D benefit. The first benefit group (Silver) had the Part D standard drug benefit threshold ($2250) while the second (Gold) had an enhanced benefit with a higher threshold ($3500). Poisson, zero-inflated Poisson, and negative binomial modeling were used to compare post-implementation utilization rates with adjustment for pre-period utilization, demographics and morbidity burden. RESULTS: A total of 1237 (6%) Silver and 526 (8%) Gold beneficiaries reached their threshold. Among both groups, beneficiaries who reached their threshold had greater morbidity burden and higher rates of pre-period inpatient admissions and medical office and ED visits (all p < 0.001). Among beneficiaries who reached their threshold, there was no change in inpatient and ED (both p > 0.05) but an increase in medical office visit (p < 0.001) utilization rates in comparable 6-month periods before and after reaching their threshold. Sub-analyses indicated that beneficiaries with the highest morbidity burden experienced higher utilization rates (all p < 0.05), but there were no differences between groups (all p > 0.05). Beneficiaries in both groups who did reach their threshold had higher post-period utilization rates (all p < 0.001) regardless of age and morbidity burden and were more likely to die (p < 0.001) compared to beneficiaries who did not reach their threshold. CONCLUSION: Although many Medicare beneficiaries navigate their drug spend threshold without experiencing increased health care utilization, those with high morbidity burdens are at risk of increased health care utilization and the potential for adverse outcomes. It is imperative that strategies be developed that help safeguard vulnerable Medicare beneficiaries.
MD6

INFLUENCE OF MEDICARE CLAIM-PAYING AGENTS' REIMBURSEMENT POLICY ON G-CSF CHOICE DURING FIRST CYCLE OF CHEMOTHERAPY FOR NON-HODGKIN'S LYMPHOMA PATIENTS
Pan X 1 , Brooks JM 2 , Wright KB 1 ,Voelker MD 1 1 University of Iowa, Iowa City, IA, USA, 2 USRDS Economic Special Study Center, The University of Iowa, Iowa City, IA, USA OBJECTIVE: Investigate the variation in Medicare claim-paying agents (carriers) reimbursement to physicians for chemotherapy and evaluate the influence of Medicare carrier chemotherapy reimbursement on G-CSF choice. G-CSF is an expensive drug to manage febrile neutropenia with uncertain benefits. METHODS: Using the national SEER-Medicare linked database, we studied patients 66 years or older diagnosed as NHL in one of the 13 SEER registry areas from 1994-2002. We grouped counties within SEER based on Medicare carrier coverage. We then estimated a regression model describing total physician reimbursement during the first cycle of chemotherapy (total Medicare part B and Medicare outpatient reimbursements within 21 days of the chemotherapy start date) to construct average Medicare chemotherapy physician reimbursement measures for these county groups. Logistic regression was performed to assess the influence of Medicare carrier chemotherapy reimbursement on the use of G-CSF. RESULTS: F test from the regression model showed statistically significant variation in the reimbursement for first cycle chemotherapy by counties grouped by carrier coverage (P value = 0.0017). We found that Medicare carrier-related chemotherapy reimbursement had a non-linear relationship with the use of G-CSF. Both linear and squared reimbursement terms were statistically significant. An increase in chemotherapy reimbursement from initially low reimbursement levels resulted in a decrease in the use of G-CSF and this relationship went away at higher chemotherapy reimbursement levels. CONCLUSION: Medicare physician reimbursement for chemotherapy varies across Medicare carriers and this variation affects the decision of physicians to prescribe G-CSF. At low chemotherapy reimbursement levels, increases in chemotherapy reimbursements decreases G-CSF prescribing. Physicians appear to compensate for lower reimbursements by increasing the intensity of their services.
MD7 DIFFERENTIAL TAKE-UP OF THE MEDICARE PART D PRESCRIPTION DRUG BENEFIT
Rabbani A 1 ,Yin W 1 , Zhang JX 1 , Sun SX 2 , Alexander GC 1 1 University of Chicago, Chicago, IL, USA, 2 Walgreens Health Services, Deerfield, IL, USA OBJECTIVE: Little is known about how Medicare Part D utilization varies based on subjects' pre-Part D prescription coverage and comorbidities. METHODS: We examined claims from a national pharmacy chain from 2005 and 2006 accounting for approximately 15% of the U.S. prescription drug market. We focused on beneficiaries ages 66-79 as of January 1, 2006. We focused on the association between pre-Part D insurance gener-osity, comorbid burden using a method of risk adjustment based on pharmacy claims, and Part D uptake after adjusting for patients' demographic characteristics, characteristics of pre-Part D prescription use (average 2005 annual copayments, number of prescriptions, drug utilization in pill-days, number of treatment classes as reported in the store data), pre-Part D Medicaid eligibility, and zip code linked USA Census data. RESULTS: After multivariate adjustment, each 10% increase in 2005 insurance generosity was associated with a 16% lower likelihood of Part D utilization and each standard deviation increase in comorbid score was associated with an 8% greater likelihood of Part D utilization. Beneficiaries with the lowest yet positive insurance generosity with the greatest comorbid burden were up to 2.5 times more likely to utilize Part D than people who had generous insurance and were the healthiest before the introduction of the program (60.65% vs. 37.56%, p < 0.001). Results were robust to numerous sensitivity analyses. CONCLUSION: We find significantly higher rates of benefit adoption among subjects with low pre-Part D prescription coverage and high pre-Part D comorbid burden. Our findings highlight the fact that implementation and uptake of changes in health policy are seldom uniform. These results also may be useful in welfare analyses of Part D, and they demonstrate the importance of considering non-random selection into Part D when considering the impact of Part D on processes or outcomes of care.
MD8 THE IMPACT OF MEDICARE NEW DRUG BENEFIT (PART D) ON THE UTILIZATION OF PSYCHOTROPIC MEDICATIONS AND CONSEQUENT OUT OF POCKET EXPENDITURE FOR ELDERLY
Chen H 1 , Nwangwu A 1 , Aparasu R 1 , Sun SX 2 , Lee KY 2 1 University of Houston, Houston, TX, USA, 2 Walgreens Health Services, Deerfield, IL, USA OBJECTIVE: To evaluate the effect of Medicare new drug benefit (Part D) on utilization of psychotropic medications and the consequent financial burden for elderly. METHODS: The effect of Medicare Part D was measured using 24 months pharmacy claims collected from one of the largest retail pharmacy chains in the United States. Among the approximately 70 million individuals who filled prescriptions at the pharmacy chain in 2006, 11% were 65 years or older. Segmented regression of interrupted time series analysis was employed to evaluate population level changes in the utilization of three most commonly used psychotropic therapeutic categories among elderly, namely antidepressants, antipsychotics and benzodiazepines. RESULTS: Since Part D came into effect, the proportion of out-of-pocket payment in total pharmacy reimbursement decreased 18% for antidepressants (net saving: $4.5 per prescription) and 21% for antipsychotics (net saving: $5.7 per prescription). In contrast, the outof-pocket share the elderly paid for benzodiazepines increased 19% (net increase: $2.8 per prescription). Part D implementation was associated with significant month-to-month increase in use of antidepressants [1679 prescriptions per month (95%CI:719, 2639)] and antipsychotics [567 prescriptions per month (95% CI:413, 720)]. By December 2006, the antidepressant and antipsychotic prescriptions filled by seniors grew 7% (from 273,166 to 293,590 prescriptions per month, P < 0.001) and 18% (from 41,079 to 48,276 prescriptions per month, P < 0.001) respectively as compared to the expected level estimated based on prior Part D trend. In contrast, Part D led to an immediate and sustained drop of 5% (from 238,961 to 226,622 prescriptions per month, P < 0.001) in benzodiazepine prescriptions filled by elderly. CONCLUSION: Our findings revealed that Medicare Part D improved the access to psychotropic medications covered under plan through reducing out-of-pocket expenses. However, the financial burden related to psychotropic medications excluded from the Part D formulary, such as benzodiazepines, has significantly increased.
RESEARCH ON PATIENT REPORTED OUTCOMES METHODS
PM1 RASCH RATING SCALE ANALYSIS OF THE EQ-5D USING THE 2003 MEDICAL EXPENDITURE PANEL SURVEY (MEPS)
Gu NY, Doctor JN University of Southern California, Los Angeles, CA, USA The aim of this study was to assess the Rasch measurement properties of the EQ-5D in respondents with most prevalent chronic conditions. Medical Expenditures Panel Survey (MEPS) respondents' age Ն 18 with complete EQ-5Ds from 2003 were extracted (n = 19,439). Eleven subgroups were identified using the primary ICD-9-CM code for the top 10 chronic conditions (hypertension, diabetes, depression, back disorder, arthropathy, cholesterol, asthma, sinusitis, anxiety and joint disorder) as well as healthy persons (n = 8021). Respondents with perfect scores demonstrating ceiling (n = 3911) and floor effects (n = 3) were removed to ensure uncertainty in the responses. Coding reflected that higher scores represent healthier respondents. The Rasch rating scale model was used to estimate one set of thresholds for all items. Unidimensionality was assessed using a z-score fit statistic, point-biserial correlations and Rasch residual factor analysis. Differential item functioning (DIF) was investigated in a pooled analysis of the 11 subgroups. Qualitative advances of the thresholds and positive point-biserial correlations were found on the EQ-5D items in all subgroups. Residual factor analysis revealed that a single factor explained between 74.9% and 94.4% of the variance. Further, respondents with different diseases demonstrated different orders of item difficulty. However, the item "anxiety/depression" consistently showed misfit (z-score > 2.0) in all subgroups. Overall, differential item functioning was found across the 11 subgroups, suggesting that respondents with different health conditions endorsed items with different frequency. For the most part, items in the EQ-5D contribute to a single underlying construct and may be used to evaluate different disease conditions. However, consistent item misfit of the "anxiety/depression" item in all subgroups suggests that a possible modification on this item may be needed.
PM2 WHAT PATIENTS SAY VS. WHAT PATIENTS MEAN: QUALITATIVE RESEARCH IN PRO DEVELOPMENT
Lasch KE 1 , Marquis P 1 ,Vigneux M 2 , Abetz L 3 , Arnould B 2 , Bayliss MS 1 , Crawford B 1 , Rosa K 1 , Scott J 1 1 Mapi Values, Boston, MA, USA, 2 Mapi Values, Lyon, France, 3 Mapi Values Limited, Bollington, UK The value of qualitative research in the development of Patient-Reported Outcome (PRO) measures has been recognized for many years. Very little information is available, however, in the PRO field on the conduct and analysis of qualitative research compared to the plethora of literature that is readily available on psychometrics. More recently, the focus has been placed on the concepts being measured and their meaning, and not in terms of correlation coefficients or factorial structure, but in their authenticity for patients. This paper that is authored by an international, interdisciplinary group of psychologists, psychometricians, regulatory experts, a physician, and a sociologist presents a method for developing PROs that are based on a foundation of Abstracts
